Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $541

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $592 to $541.
byBenzinga Newsdesk
August 1, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $592 to $541.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What Is The Trump Factor? Justice Dept’s Impact On Cannabis Rescheduling, Stocks And Investments

By Nicolas Jose Rodriguez
June 18, 5:03 PM
Equity research firm Zuanic & Associates convened a panel in mid-June featuring industry experts to dissect the ongoing cannabis rescheduling efforts in the US. They provided a comprehensive outlook on the rescheduling process, expected to conclude with the publication of the Final Rule in the Federal Register by November 2024.

CRLBF